

**Table S1.** Sequence of primers used in qPCR.

<b>Primers</b>	<b>Sequence</b>
<i>B2M</i>	<i>B2M</i> F: AGCAGAGAATGGAAAGTCAAA <i>B2M</i> R: TGTTGATGTTGGATAAGAGAA
<i>IL-1<math>\beta</math></i>	<i>IL-1<math>\beta</math></i> F: ACAGGATATGGAGCAACAAGTGG <i>IL-1<math>\beta</math></i> R: GGGCTTATCATCTTTCAACACGC
<i>IL-6</i>	<i>IL-6</i> F: GATTCCAAAGATGTAGCCGCC <i>IL-6</i> R: ATTTTCACCAGGCAAGTCTCCTC
<i>IL-10</i>	<i>IL-10</i> F: ACCCACTTCCCAGGCAACC <i>IL-10</i> R: TGGCAACCCAGGTAACCCTT
<i>TNF<math>\alpha</math></i>	<i>TNF<math>\alpha</math></i> F: CAGGCGGTGCTTGTTCTT <i>TNF<math>\alpha</math></i> R: GGGGTTCGAGAAGATGATCTGAC

F – primer forward; R – primer reverse.

**Table S2.** Transcriptional levels of inflammatory markers analyzed in breast cancer patients undergoing chemotherapy at a university hospital in Uberlândia, Minas Gerais, Brazil, 2014-2015.

<b>Inflammatory Markers</b>	<b>N</b>	<b>Median (p25-p75)</b>
<i>IL-1<math>\beta</math></i>	22	1.11 (0.65-2.77)
<i>IL-6</i>	23	0.28 (0.14-0.72)
<i>IL-10</i>	23	1.06 (0.43-3.58)
<i>TNF<math>\alpha</math></i>	20	1.24 (0.48-3.98)

*IL-1 $\beta$* , Interleukin-1 $\beta$  (n = 22); *IL-6*, Interleukin-6 (n = 22); *IL-10*, Interleukin-10 (n = 23); *TNF- $\alpha$* , Tumor Necrosis Factor  $\alpha$  (n = 20). Non-normal distribution.

**Table S3.** Plasma antioxidant markers in breast cancer patients undergoing chemotherapy at a university hospital in Uberlândia, Minas Gerais, Brazil, 2014-2015 (Median/mean and Percentiles/SD), n = 43.

<b>Antioxidant Markers</b>	<b>Median (p25-p75)</b>
	<b>Mean <math>\pm</math> SD</b>
GR	0.65 $\pm$ 0.49
GPx	6.51 $\pm$ 1.66
GSH	3.82 $\pm$ 0.81
CAT	0.13 $\pm$ 0.63
SOD <sup>a</sup>	0.10 (0.09-0.12)

GR, Glutathione Reductase; GPx, Glutathione Peroxidase; GSH, Reduced Glutathione; SOD, Superoxide Dismutase; CAT, Catalase; SD, Standard Deviation. <sup>a</sup> Non-normal distribution (the others have a normal distribution).

**Table S4.** Characterization of women who presented post-treatment metastasis - data obtained in 2019 (N = 9 for metastatic cases and N = 46 for non-metastatic cases).

<b>Patient</b>	<b>TACd</b>	<b>DII</b>
<b>ID1</b>	8.753	2.59
<b>ID2</b>	5.831	3.21
<b>ID3</b>	8.655	2.17
<b>ID4</b>	4.588	-0.41
<b>ID5</b>	10.196	1.13
<b>ID6</b>	2.784	1.87
<b>ID7</b>	4.435	2.19
<b>ID8</b>	2.047	1.89
<b>ID9</b>	11.477	-0.84

<b>Metastasis cases</b>		
<b>Median (p25-p75)</b>	5.83 (3.61 – 9.47)	1.90 (0.36 – 2.39)
<b>Non-metastasis cases</b>		
<b>Median (p25-p75)</b>	13.83 (7.93 – 21.22)	1.89 (1.21 – 2.45)

TACd, total antioxidant capacity of the diet; ID, identification; DII, dietary inflammatory index; metastasis cases, occurrence of metastases after T2 (n = 9); non-metastasis cases, no metastasis after T2 (n = 46).